Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C24H34N8O4S2.ClH |
| Molecular Weight | 599.169 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 2 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.C\C(N(CC1=CN=C(C)N=C1N)C=O)=C(/CCO)SS\C(CCO)=C(\C)N(CC2=CN=C(C)N=C2N)C=O
InChI
InChIKey=VFKAKLWCYOVTIN-LBQDPBSMSA-N
InChI=1S/C24H34N8O4S2.ClH/c1-15(31(13-35)11-19-9-27-17(3)29-23(19)25)21(5-7-33)37-38-22(6-8-34)16(2)32(14-36)12-20-10-28-18(4)30-24(20)26;/h9-10,13-14,33-34H,5-8,11-12H2,1-4H3,(H2,25,27,29)(H2,26,28,30);1H/b21-15-,22-16-;
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C24H34N8O4S2 |
| Molecular Weight | 562.708 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 2 |
| Optical Activity | NONE |
DescriptionCurator's Comment: Description was created based on several sources, including http://www.mims.com/malaysia/drug/info/neurobion/?type=full
Curator's Comment: Description was created based on several sources, including http://www.mims.com/malaysia/drug/info/neurobion/?type=full
Thiamine disulfide is a vitamin B1 derivative. It is used as a component of vitamin complexes for the treatment of neurological and other disorders associated with disturbance of metabolic functions influenced by B-complex vitamins, including diabetic polyneuropathy, alcoholic peripheral neuritis and post-influenzal neuropathies, for the treatment of neuritis and neuralgia of the spinal nerves, especially facial paresis, cervical syndrome, low back pain, and ischialgia. It has being shown to be a potent inhibitor of human immunodeficiency virus (type-1) production, suggesting that thiamine disulfide may be important for AIDS chemotherapy.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/4093890
Curator's Comment: shown in rats
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: WP3493 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7999140 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Neurobion Approved UseIndications / Uses
Film-Coated Tablet: Neurological and other disorders associated with disturbance of metabolic functions influenced by B-complex vitamins, including diabetic polyneuropathy, alcoholic peripheral neuritis and post-influenzal neuropathies.
Treatment of neuritis and neuralgia of the spinal nerves, especially facial paresis, cervical syndrome, low back pain, and ischialgia.
Injection: Treatment of disorders of the peripheral nervous system: Polyneuritis, neuralgia, sciatica and shoulder-arm syndrome, lumbago-lumbalgia, intercostals neuralgia, trigeminal neuralgia, facial palsy, herpes zoster, diabetic neuropathy, optic neuritis, numbness of the extremities; as a supplement to the therapy with isoniazid, reserpine and the phenothiazines; hyperemesis gravidarum, vitamin B deficiency, cerebrovascular accidents.
Supplement therapy with isoniazid, resperpine and phenothiazines. |
|||
| Primary | Neurobion Approved UseIndications / Uses
Film-Coated Tablet: Neurological and other disorders associated with disturbance of metabolic functions influenced by B-complex vitamins, including diabetic polyneuropathy, alcoholic peripheral neuritis and post-influenzal neuropathies.
Treatment of neuritis and neuralgia of the spinal nerves, especially facial paresis, cervical syndrome, low back pain, and ischialgia.
Injection: Treatment of disorders of the peripheral nervous system: Polyneuritis, neuralgia, sciatica and shoulder-arm syndrome, lumbago-lumbalgia, intercostals neuralgia, trigeminal neuralgia, facial palsy, herpes zoster, diabetic neuropathy, optic neuritis, numbness of the extremities; as a supplement to the therapy with isoniazid, reserpine and the phenothiazines; hyperemesis gravidarum, vitamin B deficiency, cerebrovascular accidents.
Supplement therapy with isoniazid, resperpine and phenothiazines. |
Doses
| Dose | Population | Adverse events |
|---|---|---|
50 mg single, intravenous Recommended Dose: 50 mg Route: intravenous Route: single Dose: 50 mg Sources: |
unknown, ADULT Health Status: unknown Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: |
Other AEs: Exanthema... |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Exanthema | 50 mg single, intravenous Recommended Dose: 50 mg Route: intravenous Route: single Dose: 50 mg Sources: |
unknown, ADULT Health Status: unknown Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: |
Sample Use Guides
In Vivo Use Guide
Curator's Comment: In severe cases maybe injected: 1 amp daily by deep IM (intragluteal). Milder Cases/Follow-Up Therapy: 1 amp IM 2-3 times weekly. Each 3-mL ampoule contains the following 3 essential neurotropic vitamins of the B group: Vitamin B1 (thiamine hydrochloride) 100 mg, vitamin B6 (pyridoxol hydrochloride) 100 mg, vitamin B12 5000 mcg.
1 tab of Neurobion 3 times daily to treat moderate cases
Each film-coated Neurobion tablet contains vitamins B1 (thiamine disulfide) 100 mg, vitamin B6 (pyridoxine hydrochloride) 200 mg and vitamin B12 (cyanocobalamin) 200 mcg.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7999140
Thiamine disulfide (500 uM) blocked 99.7% of HIV-1 production after 96 hr culture in acute HIV-1 (LAV-1) infection
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 21:20:14 GMT 2025
by
admin
on
Mon Mar 31 21:20:14 GMT 2025
|
| Record UNII |
JDH3946S7Y
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
18642-10-9
Created by
admin on Mon Mar 31 21:20:14 GMT 2025 , Edited by admin on Mon Mar 31 21:20:14 GMT 2025
|
PRIMARY | |||
|
JDH3946S7Y
Created by
admin on Mon Mar 31 21:20:14 GMT 2025 , Edited by admin on Mon Mar 31 21:20:14 GMT 2025
|
PRIMARY | |||
|
3038096
Created by
admin on Mon Mar 31 21:20:14 GMT 2025 , Edited by admin on Mon Mar 31 21:20:14 GMT 2025
|
PRIMARY | |||
|
m10719
Created by
admin on Mon Mar 31 21:20:14 GMT 2025 , Edited by admin on Mon Mar 31 21:20:14 GMT 2025
|
PRIMARY | Merck Index |